Ozempic, Wegovy and Mounjaro have recently gained attention for their effectiveness in weight loss. All of which are GLP-1 (glucagon-like peptide 1) receptor agonists primarily used for managing type 2 diabetes and, more recently, for weight management. These medications mimic the action of GLP-1, a hormone that is produced when we eat, helping to regulate blood sugar, promotes the release of insulin, and reduces appetite, however they can lead to a range of side effects such as nausea, vomiting, digestive issues and nutrient deficiencies. Rapid weight loss may also lead to decreased bone density and muscle mass which is a risk factor of osteoporosis.